The nation of Zimbabwe has rejected a substantial American health deal valued at 367 million US dollars (£272m) spanning five years due to the United States' demand for sensitive biological samples.
The decision came to light after a government memo from December was leaked, indicating that President Emmerson Mnangagwa felt the arrangement was "skewed".
A government representative has since explained that the United States was seeking genetic material for research and commercial purposes while was unwilling to share the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable task of scaling back our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged more talks to secure a deal acceptable to both sides so the nation's critical HIV programme can continue.
Broader Context
Zimbabwe's decision follows a similar situation in Kenya, where a court halted a similar health funding agreement after legal challenges were raised about the security of Kenyans' health data.
Since returning to office recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had managed aid for the American government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral deals to boost openness and accountability.
Based on reports, 16 African countries have to date agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration could have provided extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to surrender its biological resources and data over an extended period, with no equivalent guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that provided information," his statement read.
"Effectively, our nation would provide the raw materials for medical research with no certainty that the end products would be accessible to our people if a new health crisis arise."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of one-on-one health agreements were disrupting frameworks previously established through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This framework is designed to guarantee that when a nation contributes its data, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to continued discussions with our American counterparts on how future co-operation could be arranged in a way that respects the independence and dignity of both nations."
Medical Community Response
Medical experts said it acknowledged the government's concerns, but urged that talks need to persist considering a large portion of the country's Aids initiatives relied on external financing.
"Where specific concerns exist, such as those relating to information security or implementation frameworks, these can often be resolved via detailed discussion and mutually agreed protections," it said.
The halted deal highlights the ongoing tensions between receiving vital international aid and protecting national sovereignty in an increasingly data-driven world.